(Q45454469)

English

Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Buti M

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Jardi R

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Rodriguez-Frias F

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Valdes A

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Schaper M

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Esteban R

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Guardia J

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1349-1356

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02503.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2005.02503.X

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45454469&oldid=2076963196"